Navigation Links
Metamark Appoints Cornelius J. Merlini Chief Commercial Officer

CAMBRIDGE, Mass., Oct. 1, 2013 /PRNewswire/ -- Metamark Genetics, Inc., a leader in the discovery of molecular prognostic and diagnostic tests for cancer, today announced that Cornelius J. Merlini, former general manager of HealthTronics Laboratory Solutions (HLS), has been appointed Metamark's Senior Vice President and Chief Commercial Officer.  In August 2013, Metamark acquired HLS, a national uropathology laboratory, from Endo Health Solutions, Inc.  Mr. Merlini will report to Metamark President and Chief Executive Officer, Shawn M. Marcell, and will join the company's senior leadership team.

"We are pleased that Cornelius has joined Metamark.  His exceptional leadership, commercial acumen, and track record bringing paradigm-changing products to market have produced transformational business growth," said Mr. Marcell.  "Cornelius already is an established leader of Metamark's newly-acquired uropathology business, where he assembled a talented, dedicated team – including a specialized national field sales force.  This commercial team nicely complements Metamark's innovative research and development efforts, and will accelerate the launch of ProMark™, our novel prostate cancer prognostic test."

"Metamark's strong science engine fits perfectly with its new commercial and operational machine," said Mr. Merlini.  "ProMark™ could redefine the management of early stage prostate cancer and become a standard test sought by patients and ordered by urologists when making well-informed treatment decisions.  It is exciting to join a company that could change the way prostate cancer is treated." 

Mr. Merlini has over twenty-five years of life science experience across a wide array of functions and businesses.  Prior to HealthTronics Lab Solutions, Mr. Merlini was SVP, Commercial Operations at Cord Blood Registry, a market leader in cord blood stem cell banking.  He spent ten years with increasing marketing, management and franchise leadership responsibilities at Johnson & Johnson, where he served most recently as Worldwide Vice-President of the cardiovascular franchise for Johnson & Johnson's biopharmaceutical business.  Earlier, Mr. Merlini gained successful sales and sales leadership experience with Marion Laboratories (now Sanofi-Aventis). 

About Metamark

Metamark Genetics, Inc. is a privately held biotechnology company founded in 2007 to develop novel, function-based prognostic and diagnostic tests aimed at improving cancer care.  The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon and breast cancers.  In early 2014, Metamark plans to commercialize ProMark™ – its prostate cancer prognostic test – through its Cambridge, Massachusetts CLIA-certified laboratory.  For more information, please visit the company's Website at  Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc.

SOURCE Metamark Genetics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
2. ACTUS Appoints New Members to Its Management Team
3. Immune Design Appoints Stephen R. Brady Chief Business Officer
4. DiaVacs, Inc. Appoints Orville Kolterman, M.D. As Chief Medical Officer
5. Sanomedics International Holdings, Inc. appoints new Chairman of the Board and installs new Director of Business Development.
6. Solulink Appoints Life Science Industry Veteran Jack Ball as Chief Executive Officer
7. Cold Spring Harbor Laboratory Appoints Teri F. Willey to Accelerate Commercialization Efforts
8. Senn Chemicals Appoints New Chief Executive Officer
9. Novelda Appoints Alf-Egil Bogen as Chief Executive Officer to Lead the Company to the Next Level
10. Creabilis Appoints Professor Gil Yosipovitch and Professor Praveen Anand to its Scientific Advisory Board
11. Alexander Proudfoot Appoints Executive Vice President for Life Sciences
Post Your Comments:
(Date:6/27/2016)...  Sequenom, Inc. (NASDAQ: SQNM ), a ... the development of innovative products and services, announced today ... States denied its petition to review decisions ... U.S. Patent No. 6,258,540 (",540 Patent") are not patent ... Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, ... faculty of the University of North Carolina Kenan-Flagler Business School effective ... at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
Breaking Biology Technology:
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):